Senseonics Eversense® CGM Launches Integration with Glooko
Eversense long-term CGM and Glooko.
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of
a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the integration of
Eversense CGM data into the Glooko diabetes data management platform.
This integration allows Eversense CGM data to be synced into Glooko’s platform directly from the Senseonics cloud. Eversense
users will be able to view historical glucose and related data both in Glooko’s Mobile and Web Apps while continuing to get
real-time readings from their Eversense Mobile App. Healthcare professionals can now view their patients’ data in the Glooko
Population Tracker in interactive reports alongside other data residing in Glooko.
“Glooko has a large database of millions of users who are now able to see a clearer picture of their glucose profiles by
integrating Eversense CGM data,” said Tim Goodnow, President and CEO of Senseonics. “With personalized medicine at the forefront of
health care, data integration between Eversense CGM and Glooko helps provide customized data for users, as well as healthcare
providers. We believe this information can empower our community to help manage their diabetes with new insights and actions and,
ultimately, improve lives.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data
communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and
first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body
vibratory alerts for high and low glucose and that can be removed, recharged and re-adhered without discarding the sensor. The
sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
"We are excited to launch support for the breakthrough Eversense CGM on the Glooko platform,” said Russ Johannesson, CEO of
Glooko. “Eversense is an innovative solution for making glucose data more accessible, and we feel users will get tremendous value
out of seeing this data correlated with food, activity, and medication information they log in Glooko to help them make treatment
decisions."
Patients who are interested in getting started on Eversense can sign up at
www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners or physician assistants interested in offering the
Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in
persons age 18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose
monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense CGM System is a prescription
device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of
transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the
skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a
mobile app on the user's smartphone.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes (PWDs) and their
care teams. The Glooko product suite contains the diasend® and Glooko diabetes management solutions, which integrate with many of
the leading EHR systems used today. Both systems sync data from 190+ of the world’s most popular diabetes devices, major fitness
and activity trackers and supplies personalized, timely patient data such as glucose level, food, insulin, medications, blood
pressure and weight data. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million PWDs and are
used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting
www.glooko.com.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about
the completion and results of the integration of its Eversense and Glooko platforms, and the benefits, advantages and convenience
such integration offers people with diabetes, and other statements containing the words “believe,” “expect,” “intend,” “may,”
“projects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a
result of various important factors, including: uncertainties in the development and regulatory approval processes, uncertainties
inherent in the commercial launch and commercial expansion of the Eversense product, and such other factors as are set forth in the
risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2017, Senseonics’ Quarterly Report
on Form 10-Q for the quarter ended September 30, 2018, and Senseonics’ other filings with the SEC under the heading “Risk Factors.”
In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof.
Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics
may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation
to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as
of any date subsequent to the date hereof.
Senseonics Investor Contact
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
investors@senseonics.com
Senseonics Media Contact:
SignalWest Public Relations
Jeff Christensen, 831-566-0275
jeff@signalwestpr.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005289/en/